| BUPRENORPHINE | None | ||
| 100MG/0.5ML, 300MG/1.5ML |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| SUBLOCADE contains buprenorphine, a partial opioid agonist, and is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a buprenorphine containing product, followed by dose adjustment for a minimum of 7 days. SUBLOCADE should be used as part of a complete treatment program that includes counseling and psychosocial support. | |||
|
Yes
| |||
| SUBLOCADE | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||||||
| ********** ******** *********** ********** ************* | ********** ******** *********** ********** ************* | ********** ******** *********** ************* | ********** ******** *********** ********** ************* | ********** *********** ********** ************* | ********** ******** *********** ********** ************* | ********** ******** *********** ********** ************* | ********** ******** *********** ********** ************* | ********** ******** *********** ********** ************* | ******* ** ***** ****** *** ******** | ************* ****** ******** | ************* ****** ******** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|